While I am sure Grunenthal want the global rights and appear to have a large sale force, I am not sure they have the financial capability to do so. Hard to tell with a private company, but they did publish the below:
https://www.grunenthal.com/-/media/projects/corporatewebsite/_shared/pdf/publications/en/grunenthal_report_2018_2019.pdf
There EBITDA quoted was 0 and they have been actively acquiring assets since 2016, feels like TEVA to me. The only way they could get the US assets IMO is a very high royalty share with very low upfront. I like J&J with their balance sheet and pain med position.
While I am sure Grunenthal want the global rights and appear to...
-
- There are more pages in this discussion • 17,286 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24758 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 73626 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |